---
schema_version: "secwatch.filing_event.v1"
accession: "0001724521-25-000107"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2025-10-06T23:59:59+00:00"
generated_at: "2026-05-17T04:36:11.666567+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arcus reports ARC-20 Phase 1/1b data: pooled ORR 31%, median PFS 12.2 mo; unveils 5 I&I preclinical programs

## Summary
- ARC-20 pooled analysis (n=121) in ccRCC: 31% confirmed ORR [95% CI 23-40], median PFS 12.2 mo (9.4-20.6).
- 50 mg QD cohort showed 36% ORR (incl. pending) and median PFS 19.2 mo; 100 mg QD showed 42% ORR (incl. pending).
- Safety: Grade≥3 anemia 41%, hypoxia 11%; discontinuation rate 3%; no unexpected signals as of Aug 15, 2025 DCO.
- Five new preclinical programs disclosed: MRGPRX2, TNFR1, CCR6, CD89, CD40L; first clinical study targeted in 2026.

## SEC filing metadata
- accession: 0001724521-25-000107
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2025-10-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000172452125000107/0001724521-25-000107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000172452125000107/rcus-20251006.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001724521-25-000107
- JSON: https://secwatch.observer/filing/0001724521-25-000107.json
- Plain text: https://secwatch.observer/filing/0001724521-25-000107.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.